Clinical significance of multiprobiotics in the management of patients with infectious pathology
I. N. Zakharova,
I. V. Berezhnaya,
K. K. Baranov,
A. V. Gorelov,
K. D. Ermolenko,
Yu. V. Lobzin,
V. P. Novikova https://doi.org/10.21518/ms2026-050
Abstract
At the Department of Pediatrics of the Russian Medical Academy of Continuing Professional Education (RMANPO) named after G.N. Speransky an Expert Council meeting was held to explore the issues of safe antibacterial therapy, various aspects of microbiota-microorganism interactions, and the possibilities that it opens up for health service practices.
About the Authors
I. N. Zakharova
Russian Medical Academy of Continuing Professional Education (RMANPO)
named after G.N. Speransky
Russian Federation
Russian Federation
I. V. Berezhnaya
Russian Medical Academy of Continuing Professional Education (RMANPO)
named after G.N. Speransky
Russian Federation
Russian Federation
K. K. Baranov
Федеральный научно-клинический центр физико-химической медицины имени академика Ю.М. Лопухина Федерального медико-биологического агентства; Российский национальный исследовательский медицинский университет имени Н.И. Пирогова
Russian Federation
Russian Federation
A. V. Gorelov
Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)
Russian Federation
Russian Federation
K. D. Ermolenko
Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства России
Russian Federation
Russian Federation
Yu. V. Lobzin
Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства России
Russian Federation
Russian Federation
V. P. Novikova
Санкт-Петербургский государственный педиатрический медицинский университет
Russian Federation
Russian Federation
References
1. Queen J, Zhang J, Sears CL. Oral antibiotic use and chronic disease: long-term health impact beyond antimicrobial resistance and Clostridioides difficile. Gut Microbes. 2020;11(4):1092–1103. https://doi.org/10.1080/19490976.2019.1706425.
2. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;400(10358):1102. https://doi.org/10.1016/S0140-6736(21)02653-2.
3. O’Neill J. The Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. 2014.
4. Fedotova MM, Akperov EG, Eliseev VYu, Kostyaeva MYa, Olenius DD, Kiseleva AL et al. Antibiotic therapy for acute respiratory viral infections in children: what do parents know about antibiotics and antibiotic resistance? Clinical Practice in Pediatrics. 2022;17(2):85–92. (In Russ.) https://doi.org/10.20953/1817-7646-2022-2-85-92.
5. Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60(1):49–54. https://doi.org/10.1136/gut.2010.219683.
6. Mundy LM, Sahm DF, Gilmore M. Relationships between enterococcal virulence and antimicrobial resistance. Clin Microbiol Rev. 2000;13(4):513–522. https://doi.org/10.1128/CMR.13.4.513.
7. Bosch AATM, de Steenhuijsen Piters WAA, van Houten MA, Chu MLJN, Biesbroek G, Kool J, et al. Maturation of the Infant Respiratory Microbiota, Environmental Drivers, and Health Consequences. A Prospective Cohort Study. Am J Respir Crit Care Med. 2017;196(12):1582–1590. https://doi.org/10.1164/rccm.201703-0554OC.
8. Turck D, Bernet JP, Marx J, Kempf H, Giard P, Walbaum O et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003;37(1):22–26. https://doi.org/10.1097/00005176-200307000-00004.
9. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563–578. https://doi.org/10.2217/17460913.3.5.563.
10. King AM, Mackin KE, Lyras D. Emergence of toxin A-negative, toxin B-positive Clostridium difficile strains: epidemiological and clinical considerations. Future Microbiol. 2015;10(1):1–4. https://doi.org/10.2217/fmb.14.115.
11. Schwan C, Stecher B, Tzivelekidis T, van Ham M, Rohde M, Hardt WD et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog. 2009;5(10):e1000626. https://doi.org/10.1371/journal.ppat.1000626.
12. Panda S, El khader I, Casellas F, López Vivancos J, García Cors M, Santiago A et al. Short-term effect of antibiotics on human gut microbiota. PLoS ONE. 2014;9(4):e95476. https://doi.org/10.1371/journal.pone.0095476.
13. Tu P, Chi L, Bodnar W, Zhang Z, Gao B, Bian X et al. Gut Microbiome Toxicity: Connecting the Environment and Gut Microbiome-Associated Diseases. Toxics. 2020;8(1):19. https://doi.org/10.3390/toxics8010019.
14. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology. 2010;156(11):3216–3223. https://doi.org/10.1099/mic.0.040618-0.
15. Wostmann BS, Larkin C, Moriarty A, Bruckner-Kardoss E. Dietary intake, energy metabolism, and excretory losses of adult male germfree Wistar rats. Lab Anim Sci. 1983;33(1):46–50. Available at: https://pubmed.ncbi.nlm.nih.gov/6834773.
16. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–1031. https://doi.org/10.1038/nature05414.
17. Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H. Antibiotics as Major Disruptors of Gut Microbiota. Front Cell Infect Microbiol. 2020;10:572912. https://doi.org/10.3389/fcimb.2020.572912.
18. Nowak A, Paliwoda A, Błasiak J. Anti-proliferative, pro-apoptotic and antioxidative activity of Lactobacillus and Bifidobacterium strains: A review of mechanisms and therapeutic perspectives. Crit Rev Food Sci Nutr. 2019;59(21):3456–3467. https://doi.org/10.1080/10408398.2018.1494539.
19. Heinemann C, van Hylckama Vlieg JE, Janssen DB, Busscher HJ, van der Mei HC, Reid G. Purification and characterization of a surface-binding protein from Lactobacillus fermentum RC-14 that inhibits adhesion of Enterococcus faecalis 1131. FEMS Microbiol Lett. 2000;190(1):177–180. https://doi.org/10.1111/j.1574-6968.2000.tb09282.x.
20. Feng T, Wang J. Oxidative stress tolerance and antioxidant capacity of lactic acid bacteria as probiotic: a systematic review. Gut Microbes. 2020;12(1):1801944. https://doi.org/10.1080/19490976.2020.1801944.
21. Li F, Duan K, Wang C, McClain C, Feng W. Probiotics and Alcoholic Liver Disease: Treatment and Potential Mechanisms. Gastroenterol Res Pract. 2016;2016:5491465. https://doi.org/10.1155/2016/5491465.
22. Sugahara H, Odamaki T, Fukuda S, Kato T, Xiao JZ, Abe F et al. Probiotic Bifidobacterium longum alters gut luminal metabolism through modification of the gut microbial community. Sci Rep. 2015;5:13548. https://doi.org/10.1038/srep13548.
23. Wang BG, Xu HB, Wei H, Zeng ZL, Xu F. Oral administration of Bifidobacterim bifidum for modulating microflora, acid and bile resistance, and physiological indices in mice. Can J Microbiol. 2015;61(2):155–163. https://doi.org/10.1139/cjm-2014-0694.
24. Gorelov AV, Melekhina ЕV, Sidelnikova ES. Development of pathogenetically justified approaches to therapy of young children with acute respiratory infections requiring antibacterial drugs. Meditsinskiy Sovet. 2019;(17):208–216. (In Russ.) https://doi.org/10.21518/2079-701X-2019-17-208-216.
25. Gorelov AV, Melekhina EV, Sidelnikova ES. Prevention of biocenosis disorders in children with acute respiratory infections receiving antibacterial therapy. RMJ. 2019;(10):26–31. (In Russ.) Available at: https://www.rmj.ru/articles/infektsionnye_bolezni/Profilaktika_narusheniy_biocenoza_u_detey_s_ostrymi_respiratornymi_infekciyami_poluchayuschih_antibakterialynuyu_terapiyu.
26. Ruzhentsova TA, Ploskireva AA, Gorelov AV. Complications of rotavirus infection in children. Pediatriya – Zhurnal im G.N. Speranskogo. 2016;95(2):38–42. (In Russ.) Available at: https://pediatriajournal.ru/files/upload/mags/351/2016_2_4563.pdf
27. Jiang L, Tang A, Song L, Tong Y, Fan H. Advances in the development of antivirals for rotavirus infection. Front Immunol. 2023;14:1041149. https://doi.org/10.3389/fimmu.2023.1041149.
28. Alagova MV, Razdyakonova IV, Samoylova IG, Ermolenko KD, Svitich OA, Ratnikova AK. Effectiveness of pathogenetic therapy for rotavirus infection in children. Infectious Diseases: News, Opinions, Training. 2025;14(3):62–70. (In Russ.) https://doi.org/10.33029/2305-3496-2025-14-3-62-70.
29. Panova LD, Khismatullina ZR, Davletbayeva GA, Panova AN, Bulatova ST. Immunoprobiotic in pediatrics: from concept to practice. Meditsinskiy Sovet. 2022;(1):212–224. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-1-212-224.
30. Zakharova IN, Koshechkin SI, Odintsova VЕ, Romanov VA, Popenko AS, Pervishko OV et al. Analysis of probiotic’s impact on the clinical manifestations and severity of acute respiratory infections. Meditsinskiy Sovet. 2024;(11):163–172. (In Russ.) https://doi.org/10.21518/ms2024-330.
31. Baranov KK, Hakobyan AN. Prevention of the development of antibiotic-associated diarrhea in patients receiving systemic antibacterial therapy for otorhinolaryngological diseases. Detskaya Otorinolaringologiya. 2024;(1-2):34–37. (In Russ.) Available at: https://mediamedichi.ru/wp-content/uploads/2024/12/Medici_KidLOR_1_2024.pdf.
Review
For citations:
Zakharova IN, Berezhnaya IV, Baranov KK, Gorelov AV, Ermolenko KD, Lobzin YV, Novikova VP. Clinical significance of multiprobiotics in the management of patients with infectious pathology. Meditsinskiy sovet = Medical Council. 2026;(1):13-22. (In Russ.) https://doi.org/10.21518/ms2026-050
Views:
272
JATS XML
Email this article 